In the Spotlight - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

In the Spotlight
New product reviews for October 2012, featuring analytical equipment.

Pharmaceutical Technology
Volume 36, Issue 10, pp. 26

Mass spectrometers increase analytical throughput

Shimadzu has added three new triple quadrupole mass spectrometers, LCMS-8040, LCMS-8080 and GCMS-TQ8030, to its UFMS series, which currently comprises seven systems. The LCMS-8040 combines improved ion optics and collision cell technology with proprietary ultrafast technologies, and provides an expanded range of ultra-fast, high-sensitivity applications. With the LCMS-8080, it is possible to conduct trace analysis of compounds in complex matrices as the system features high sensitivity with a large dynamic range and quantitation performance. The GCMS-TQ8030 achieves the highest sensitivity in its class for multiple reaction-monitoring measurements based on UFsweeper technology.

Spectrometers are available worldwide

Dynamic light-scattering system with protein measurement and microrheology capabilities

The latest addition to Malvern's Zetasizer family of dynamic light-scattering (DLS) instruments is the Zetasizer Nano ZSP, which features enhanced sensitivity and advanced software for new types of measurement. The system can measure the electrophoretic mobility of proteins and features software that controls data acquisition, guiding the user through the measurement, and assessing and reporting on data quality. In addition, a DLS-based optical technique enables the rheological characterization of weakly-structured and highly sensitive materials using microliter sample volumes.

Malvern Instruments
System is available worldwide

Bench top microwave digestion system for trace-metals analysis for USP <232> and <233>

Milestone's UltraWAVE is a benchtop microwave system that uses Single Reaction Chamber (SRC) technology to improve the sample-prep workflow for trace-metals analysis by ICP-MS/OES. The system is offered as a replacement option for both traditional open-vessel and closed-vessel digestion systems in pharmaceutical laboratories, and can enhance efficiency by increasing sample throughput while lowering labor costs. Unlike traditional digestion systems, the SRC can process multiple sample types simultaneously, and up to 15 samples can be digested at one time in less than an hour from start to finish. The unit can also handle large sample weights (5 x 2 g), previously only possible with open vessel digestion. The high-temperature (300 C) and high-pressure (199 bar) capabilities of the UltraWAVE can also result in more complete digestions and better analytical data quality.

System is available worldwide

Refrigerated/heated circulating bath for product-quality analysis

The PolyScience 75-L Refrigerated Circulating Bath is a large-capacity circulating bath that is designed for a variety of pharmaceutical applications, including compound reactions at a controlled temperature (37 C), rotary evaporator cooling and reactor–vessel temperature control. The unit features a –20 to 100 C working temperature range, a 0.005C temperature stability and a 1.8ft3 reservoir. Its Performance Programmable touch-screen temperature controller displays temperature to 1/1000 of a degree, and offers broad, user-programmable thermal cycling capabilities. Additional features include a swivelling control head that permits viewing of the temperature display anywhere within a 180 viewing radius, a corrosion- and chemical-resistant top plate that remains cooler at high temperatures, and PolyScience's WhisperCool environmental-control technology that reduces operational noise and energy consumption.

Bath is available worldwide


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here